Dr Richardson on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Related Keywords

Oklahoma ,United States ,University Of Oklahoma ,Debral Richardson , ,University Of Oklahoma Ou College Medicine ,Stephenson Cancer Center ,Phasei Program ,Ou Health ,Gynecologic Oncology ,Global Meeting ,Selinexor ,Endometrial Cancer ,Tp53 ,Siendo ,